Drugs / AFASEVIKUMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01540760 | Mar → Sep 2012 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01480310 | Dec 2011 → Jun 2012 | — | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFASEVIKUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109469 ↗ |
| Known as | MCAF5352A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01480310 ↗ |
| Known as | NI-1401 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109469 ↗ |
| Known as | RG-7624 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109469 ↗ |
| Known as | RO-5553110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109469 ↗ |
| Action | Inhibit | “Interleukin 17A inhibitor” CHEMBL2109469 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2109469 ↗ |
| Route | Subcutaneous | “subcutaneous doses of MCAF5352A” NCT01480310 ↗ |
| Target | IL17A | “Interleukin 17A inhibitor” CHEMBL2109469 ↗ |